Pharmaceutical giant Eli Lilly (NYSE:LLY) reported decent first quarter results late in April 2012. Sales and earnings both fell, but investors have come to expect operational declines at Lilly and most of its key rivals. The above-average dividend yields have been the saving grace, and could be relied on for some time, until new drugs starting boosting industry prospects again.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

First Quarter Recap
Total reported revenues fell 4% to $5.6 billion. The biggest hit was the expiration of patent protection for Zyprexa in the United States and "many international markets." Overall, the sales decline was attributed to a 7% drop in volume, though pricing increased 4%. Currency fluctuations had a minimal impact on the sales figure for the quarter. Non-U.S. sales actually declined at a faster rate than domestically, dropping 9% to $2.5 billion, or nearly 45% of the total top line.

Net income also declined 4% to just over $1 billion, as did earnings per share, which came in at 91 cents per diluted share. Lilly paid out more than half, or 49 cents per diluted share in the form of a quarterly dividend. Its annual payout rate currently stands at 4.7%.

Outlook and Valuation
For the full year, analysts project a total sales decline of nearly 7% and total sales of just under $23 billion. Lilly expects to report earnings in a range of $3.14 to $3.29 for a decline of between 16 and 19% from 2011. On an adjusted basis, it expects to report $3.15 to $3.30 for an annual decline of as much as 25%. The current consensus earnings expectation is $3.26. At the current share price of $41.43, this represents a forward P/E of 11.21.

SEE: 5 Must-Have Metrics For Value Investors

The Bottom Line
An estimated 40% of Lilly's patented drugs will see their patent protection expire within the next three years. To offset this major loss of revenue are approximately 10 Phase III compounds that could achieve blockbuster status, or the achievement of $1 billion in annual revenue.

Lilly's predicament is quite common in the industry. Merck (NYSE:MRK), GlaxoSmithKline plc (NYSE:GSK), Bristol-Myers Squibb (NYSE:BMY) and Novartis (NYSE:NVS) are all seeing a large number of blockbusters face generic competition. Lilly has committed to supporting its dividend yield, which offers a certain level of stability, as income-minded investors are likely to stay put. However, the upside potential in the stock currently looks nonexistent. Positive news on the drug pipeline could boost the stock, but it will be some time before Lilly sees an extended period of steady, sustainable sales growth.

SEE: Earning Forecasts: A Primer

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Ryan C. Fuhrmann did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    How Medtronic Makes Money (MDT)

    Here's the story of an American medical device firm that covers almost every segment in medicine and recently moved to Ireland to pay less in taxes.
  2. Investing News

    Latest Labor Numbers: Good News for the Market?

    Some economic numbers are indicating that the labor market is outperforming the stock market. Should investors be bullish?
  3. Investing News

    Stocks with Big Dividend Yields: 'It's a Trap!'

    Should you seek high yielding-dividend stocks in the current investment environment?
  4. Investing News

    Should You Be Betting with Buffett Right Now?

    Following Warren Buffett's stock picks has historically been a good strategy. Is considering his biggest holdings in 2016 a good idea?
  5. Products and Investments

    Cash vs. Stocks: How to Decide Which is Best

    Is it better to keep your money in cash or is a down market a good time to buy stocks at a lower cost?
  6. Investing News

    Who Does Cheap Oil Benefit? See This Stock (DG)

    Cheap oil won't benefit most companies, but this retailer might buck that trend.
  7. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  8. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  9. Investing News

    The UAE: An Emerging Economy for Investors

    The learning from UAE on how it succeeded with timely diversification when the BRICS nations and the neighboring oil-rich economies faced challenges.
  10. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
Trading Center